Active	Status	Sponsor type	Region	Phase	Filter
8 Active 4 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
KILADJIAN, Jean-Jacques
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) Jan 2024 - Dec 2024: Approval for myelofibrosis Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis Feb 2024 - Feb 2024: Completion of P2b trial for JIA Feb 2024 - Feb 2024: Exclusivity expiry in US	Active, not recruiting	3	430	Europe, Canada, US, RoW	Pelabresib, Ruxolitinib, Placebo	Constellation Pharmaceuticals	Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	08/23	12/27
ROP-ET, NCT06514807: A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients	Active, not recruiting	3	117	Europe, RoW	Ropeginterferon alfa-2b (BESREMi®)	AOP Orphan Pharmaceuticals AG	Essential Thrombocythaemia	03/28	03/28
MITHRIDATE, NCT04116502 / 2018-001908-11: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera	Recruiting	3	586	Europe	Ruxolitinib, Jakavi®, Hydroxycarbamide, Hydroxyurea, Interferon-Alpha, Interferon, alpha interferon, Intron® A, Roferon® A	University of Birmingham, Novartis, MPN Voice, French National Cancer Institute (Institut National Du Cancer - France)	Polycythemia Vera	10/28	04/30
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms	Recruiting	3	1308	Europe	Direct Oral Anticoagulants, Low-dose aspirin	University Hospital, Brest	Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients	07/27	07/27
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Jul 2023 - Dec 2023 : Top-line data from XPORT-MF-035 trial for myelofibrosis First patient dosed as a monotherapy in patients with 2L myelofibrosis Dec 2021 - Dec 2021: First patient dosed as a monotherapy in patients with 2L myelofibrosis	Active, not recruiting	2	112	Europe, US, RoW	Selinexor, Physician's Choice Treatment	Karyopharm Therapeutics Inc	Myelofibrosis	01/25	01/25
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia	Recruiting	2	118	Europe, Canada, US, RoW	Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA	Karyopharm Therapeutics Inc	Myelofibrosis, Moderate Thrombocytopenia	04/26	10/28
MPN-COVID, NCT04385160: Myeloproliferative Neoplasms (MPN) and COVID-19	Recruiting	N/A	552	Europe, US, RoW		Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net	Myeloproliferative Neoplasm, COVID	02/22	08/22
COVIFERON, NCT06762002: Impaired Type I IFN Immunity Due to Autoantibodies or a Genetic Defect: a Prospective National Cohort	Not yet recruiting	N/A	500	Europe	blood sample	Institut National de la Santé Et de la Recherche Médicale, France	Immunology, Allergy, Genetic Diseases, Infectious Diseases	01/29	01/29